**Name of Journal:** *World Journal of Clinical Infectious Diseases*

**Manuscript NO:** 86153

**Manuscript Type:** MINIREVIEWS

**Monkeypox in humans: Transmission, pathophysiology, diagnosis, treatment, prevention, and all recent updates**

Parikh T *et al*. Pediatric monkeypox

Taral Parikh, Ashish Goti, Kanica Yashi, Nilesh Dankhara, Sandhya Kadam, Ramesh Dihora, Kapil Paiwal, Narendrasinh Parmar

**Taral Parikh,** Department of Pediatrics, Hamilton Health Center, Harrisburg, PA 17104, United States

**Ashish Goti,** Department of Pediatric, Tulane Medical Center, New Orleans, LA 70112, United States

**Kanica Yashi,** Adult Medicine, Bassett Medical Center, Cooperstown, NY 13326, United States

**Nilesh Dankhara,** Department of Pediatric and Neonatology, University of Mississippi Medical Center, Jackson, MS 39216, United States

**Sandhya Kadam,** Department of Pediatric, Family Healthcare Network, Visalia, CA 93277, United States

**Ramesh Dihora,** Department of Pediatric, Nice Children Hospital, Surat 395003, India

**Kapil Paiwal,** Oral Maxillofacial Surgeon, Daswani Dental College and Research Center, Kota 324005, India

**Narendrasinh Parmar,** Department of Pediatrics, Brookdale University Hospital Medical Center, Brooklyn, NY 11212, United States

**Author contributions:** Parikh T, Goti A, Yashi K, Dankhara N, Kadam S, Dihora R, Paiwal K, and Parmar N contributed equally to study conception and design, data collection, analysis and interpretation of the results, and manuscript preparation.

**Corresponding author: Taral Parikh, MD, Doctor,** Department of Pediatrics, Hamilton Health Center, 110 s 17th Street, Harrisburg, PA 17104, United States. parikhtaral@yahoo.com

**Received:** June 2, 2023

**Revised:** September 21, 2023

**Accepted:** October 23, 2023

**Published online:**

**Abstract**

The Centers for Disease Control and Prevention (CDC) is monitoring an epidemic of monkeypox infection in the United States. The outbreak is now global and more than 6900 cases have already been reported. There are 83 confirmed cases among children and adolescents, as shown in the report published on November 3, 2022, in the USA. However, monkeypox in pediatric patients is still infrequent (< 0.3% of total cases). Among cases in the United States, 16 cases were in children < 5 years, 12 in the age group 5-12 years, and 55 cases in adolescents 13-17 years old. In the adolescent age group, 89% were male. For children < 12 years of age, close physical contact with an adult household with monkeypox was the primary exposure, but for adolescents, male-to-male sexual contact was found more frequently. The CDC advised United States healthcare providers to remain vigilant for patients with a rash resembling monkeypox, even if there is no history of travel to a country with high risk. This article summarizes the history and epidemiology of monkeypox with a specific emphasis on clinical features and management in pediatric patients.

**Key Words:** Pediatric monkeypox; Smallpox; Monkeypox case definition; JYNNEOS vaccine; ACAM2000

Parikh T, Goti A, Yashi K, Dankhara N, Kadam S, Dihora R, Paiwal K, Parmar N. Monkeypox in humans: Transmission, pathophysiology, diagnosis, treatment, prevention, and all recent updates. *World J Clin Infect Dis* 2023; In press

**Core Tip:** This article describescurrent updates on the clinical features and management of pediatric monkeypox infection.

**INTRODUCTION**

The monkeypox virus is an orthopoxvirus that causes monkeypox. Orthpoxviruses that infect humans range from lethal small poxviruses to highly contagious but benign molluscum contagiosum viruses[1]. Monkeypox has always been found in West and CentralAfrica. However, in May 2022, the United States and other countries reported cases of monkeypox, even though there was not previously documented monkeypox transmission[2]. There are two distinct monkeypox virus classes: The Congo basin clade, mainly in central Africa, and the West Africa clade[3]. The Congo basin clade is known to cause disease with a severe impact and causes more morbidity and mortality. Human-to-human transmission has also been reported more frequently with the Congo basin clade.

***Monkeypox in non-human primates***

The monkeypox virus was first discovered in 1958 from a monkey in Copenhagen, Denmark, at the Staten's Serum Institute —and that is how it got its name[4]; monkeypox virus-hosts also include dormice, pouched rats, rope squirrels, and tree squirrels. Like many other zoonoses, Pox virus is known to be transmitted accidentally to a human when dealing with infected animals.

***Monkeypox in humans***

The Dominican Republic (DR) of the Congo noted the first known human case of monkeypox in 1970. Six unvaccinated people from the DR of Congo, Liberia, and Sierra Leone presented with an illness similar to smallpox on clinical presentation[5]. The DR Congo reported the first pediatric case in a 9-month-old infant. Four other children from Bouduo and Liberia aged 4 to 9 years were also affected. Three children close to these cases also developed a rash in the following days, indicating possible exposure. There was also the case of the 24-year-old male reported in Sierra Leone who was reported to have removed the stomach and intestine from a red monkey, and after 3-4 wk, he felt ill. No one died of monkeypox.

In the United States, monkeypox cases were first reported in 2003[6]. Seventy-one people were infected by Gambian pouched rats and prairie dogs, when they received a shipment of these infected animals as pets. The Centers for Disease Control and Prevention (CDC) and Wisconsin Research Department mentioned this outbreak in which patients presented with febrile illness with vesiculopustular eruption between May and June 2003. The five male and six female patients were aged between 3 and 43 years. The possible epidemiology, clinical, and laboratory investigations in this outbreak were also summarized. Contact with ill pet prairie dogs exposed to sick rodents from West Africa and Ghana was identified in all these patients. The illness started with a fever with or without chills, skin rash, and excessive sweating. All patients reported papular skin rash and headache; many reported fevers, chills, sweating, or persistent cough, and approximately half of the patients had lymphadenopathy. The characteristic rash started as a papule followed by a vesiculopustular lesion surrounded by erythema. Lesions finally resolved with serous fluid and a hemorrhagic crust with a mean duration of 12 d (3-25 d). All cases had a mild disease course, and only four were hospitalized, but recovered quickly. This was the first time monkeypox was identified among humans in the Western world. Only five adults were vaccinated against smallpox, while others were too young to receive the vaccine.

An outbreak of human monkeypox occurred in Nigeria in 2017[7]. There were 38 suspected cases, of which 18 received laboratory confirmation, three cases were probable, and 17 did not meet the case definition. Most of the confirmed cases were male adults. There was an association with varicella, syphilis, and human immunodeficiency virus (HIV) in two confirmed cases, and one healthcare worker had a nosocomial infection.

In September 2018, the United Kingdom reported monkeypox transmission from a patient to a healthcare worker[8]. The possible source of infection was contaminated bedding. The hospital undertook all possible infection control measures to control the outbreak. Four of the 134 possible cases exposed became ill, but the clinical course was mild.

***Transmission***

Monkeypox infection resembles smallpox, and the illness may be initially diagnosed as smallpox as both illnesses share similar clinical features[9]. Monkeypox was identified after the eradication of smallpox. Monkeypox is a zoonosis, although human-to-human transmission can occur. Monkeypox can spread due to close or skin-to-skin contact. Direct contact with monkeypox rash and contact with the patient’s saliva, upper respiratory secretions, and areas around the anus, rectum, or vagina can lead to infection. It is not as contagious as smallpox among humans. Although monkeys and other primates are the primary reservoirs, other animals, such as squirrels and other rodents, can also be reservoir hosts for this virus. Pox virus deoxyribonucleic acid (DNA) has been identified in anal and urethral swabs from persons who neither demonstrated clinical signs nor reported symptoms of illness at the time of specimen collection. Few cases remained asymptomatic despite having known or possible sexual exposure to infected personnel[10].

***How monkeypox relates to smallpox***

In 1980 smallpox was declared eradicated worldwide, and the last reported case was in 1977. However, Huang *et al* reported that it had been over 40 years since all countries stopped administering the smallpox vaccine[11]. Previous history of vaccination against smallpox can provide some protection against monkeypox, but it is uncertain how long this protection lasts. In the 2003 monkeypox outbreak and 2022 outbreak, multiple infected patients with monkeypox had a history of smallpox vaccination in past decades[12].

***Pathophysiology***

The monkeypox virus enters the body *via* routes such as the oropharynx, nasopharynx, or intradermal and replicates at the inoculation site, then spreads to local lymph nodes[13], followed by viremia and infection of organs. The incubation period typically ranges from 7 to 14 d, with a maximum of 21 d. Symptoms start with fever and lymphadenopathy 1-2 d before developing skin lesions. In the 2022 outbreak, it was noted that monkeypox spread from when symptoms appeared to the phase where the rash had healed completely, and a new layer of skin had formed[14].

***Case definition and clinical features***

Below is the Case definition by the CDC and European Centre for Disease Prevention and Control guidance[14,15] (Table 1).

***Exclusion criteria***

Another diagnosis is made or an individual with suspected monkeypox does not develop clinical symptoms or a rash within five days or suspicious clinical specimens fail to demonstrate orthopoxvirus infection or antibodies against the infection.

***Clinical features***

Monkeypox rash begins with macules followed by papules, vesicles, and pustules. Pustules are characteristically deep-seated, firm, and well-circumscribed. These lesions can progress to become umbilicated or confluent but ultimately progress to scabs[16]. The rash can also spread to other parts of the body. Lesions on a distinct body part are at the same stage in classic monkeypox.

Classic symptomatology during monkeypox infection includes fever with chills, malaise, sore throat, and lymphadenopathy, followed by a characteristic rash. However, in the 2022 outbreak, some patients developed perianal and genital lesions but no fever or other systemic symptoms.

Monkeypox rash can mimic other common illnesses in clinical practice such as syphilis, herpes simplex virus and varicella zoster infection, chancroid, and molluscum contagiosum, and these illnesses can frequently be associated with monkeypox. Therefore, it is necessary that the clinician remains vigilant, especially with patients who present with the characteristic rash and men who practice sex with men (Table 2).

***How long is monkeypox contagious?***

As shown by Guarner *et al*[1], the infected person is not contagious during the incubation period. However, humans can be infectious as soon as symptoms begin until all scabs on the pox lesions fall off.

***Diagnosis***

When monkeypox is suspected in the United States; the clinician should contact the health department to determine the availability of testing, and lesions should be thoroughly swabbed and sent to testing laboratories. The monkeypox virus can be detected by an orthopoxviral polymerase chain reaction (PCR) test at a designated laboratory, and a positive PCR is enough for the diagnosis of monkeypox. When complex cases or positive laboratory results do not meet epidemiological criteria, the CDC should be consulted so that additional tests such as viral-specific or clade-specific PCR and blood testing can be conducted.

***Complications***

Reported complications are encephalitis, secondary skin infections, conjunctivitis, keratitis, and secondary pneumonia. During outbreaks in epidemic areas, mortality can be between 0% and 11%, affecting significantly young children[17]. Severe monkeypox infection is common in immunocompromised patients. Patients with HIV infection suffered more during the 2017 Nigeria outbreak than HIV-negative patients, with severe skin lesions and genital ulcers. However, no deaths were reported. Between September 2017 and June 2022, Nigeria reported 257 confirmed cases, with nine deaths; of the nine patients who died, five were immunocompromised[18]. Disfiguring scars and corneal damage can be frequent significant sequelae. It was noted that vaccinated patients experienced fewer complications, and the secondary case rate in such households was lower[19]. As shown by Mbala *et al*[20], pregnant patients had more complications, including preterm delivery, fetal death, or congenital diseases. An observational study was performed at the Hospital in Kole between 2007 and 2011, which showed that of four pregnant women with monkeypox, who were included in the study, one had a full-term, healthy baby, two experienced a stillbirth in the first trimester, and the remaining patient experienced fetal death.

***Precautions***

Monkeypox spreads from human to human *via* exposure to the rash, close contact, or articles contaminated with contagious inflammation or body secretions[21]. Standard care is required for all suspected monkeypox patients. People with monkeypox who are not hospitalized require isolation at home. For confirmed monkeypox, isolation must continue until the rash has healed, the scabs have fallen off, and skin is intact.

***Treatment***

As shown by Rizk *et al*[22], monkeypox does not require treatment in all patients. Immunocompromised patients, children under eight years of age, pregnant or breastfeeding women, and those with eczema or exfoliative skin lesions are considered high risk. Also, patients with severe complications or rashes involving the eyes, mouth, and private areas may qualify for treatment.

Unfortunately, there are no treatment protocols for pediatric patients with monkeypox; however, local public health officials can help with CDC consultation to initiate antiviral therapy.

Tecovirimat was developed to treat smallpox, which can be used for monkeypox and is currently the first-line treatment for children. An oral dose in children of more than 13 kg is possible, which can be taken as a capsule, or the capsule's content can be mixed with food. In children less than 13 kg, the intravenous formulation can be considered depending on clinical status. Monitoring renal function is recommended, especially in children under two years of age.

The CDC is also developing a protocol for intravenous immunoglobulin in patients with monkeypox, but its effectiveness has not been established.

Brincidofovir was Food and Drug Administration (FDA) approved for smallpox treatment, and cidofovir was FDA-approved for cytomegalovirus retinitis in acquired immunodeficiency syndrome in the pediatric population. However, there is still a lack of data on the effectiveness of brincidofoir and cidofovir in treating pediatric monkeypox.

***Post-exposure prophylaxis***

The CDC is conducting studies to determine how long immunity lasts after vaccination. They are looking at specimen samples from infected patients to determine whether the virus has changed. The CDC works closely with local and state partners to determine how the virus spreads among monkeypox patients. Studies have been carried out to assess how many patients were vaccinated, if they were fully vaccinated, and when they were vaccinated. Close monitoring of those newly diagnosed with monkeypox after vaccination is ongoing.

Two vaccines can be given to people who have been in contact with a monkeypox patient[23]. Data on post-exposure prophylaxis (PEP) in children are limited. JYNNEOS is the only vaccine that can be used in pediatrics. The decision to vaccinate must be made according to the level of risk in terms of the patient’s exposure and health conditions. While vaccination is preferred in most cases, immunoglobulin may be considered in an infant less than six months of age. There is the possibility of using anti-viral medication after consultation with the appropriate CDC facility for PEP.

***JYNNEOS***

This vaccine has not been extensively studied in pediatrics for monkeypox; it contains non-replicating vaccine virus. This vaccine has been used in pediatrics for illnesses such as tuberculosis, Ebola, and measles without major side effects. In 2018-2019, this vaccine was used in the United Kingdom in pediatrics following monkeypox exposure without any major side effects. In the current outbreak, JYNNOS is available for children and adolescents under 18 years of age, who are classified as having high-risk exposure according to the CDC[24]. The dose is 0.5 mL for each subcutaneous injection with a two-dose series, and ideally, the first dose should be given within 96 h post-exposure[24].

***ACAM2000***

As shown by Singhal *et al*[25], this vaccine contains replicating viruses associated with side effects such as uncontrolled viral replication and eczema vaccinatum. It is not a preferred vaccine for pediatrics and should only be considered if JYNNEOS is unavailable or contraindicated.

**Immunoglobulin:** Immunoglobulin is approved under the emergency authorization for the prevention of monkeypox and is preferred for infants less than six months old with high-risk exposure[26].

**CONCLUSION**

Monkeypox virus is a very contagious orthopoxvirus currently causing a global outbreak, and primarily affecting men who have sex with men. After discontinuing the smallpox vaccine, population immunity decreased and led to an increase in monkeypox cases. Furthermore, the increased number of cases outside Africa demonstrates the global spread of the disease. Obtaining control over this infection requires doctors, hospitals, and health care officials to work together and define appropriate diagnostic testing, contact tracing, and availability of medical care to the affected patient. It is very important that pediatric physicians should be aware of the clinical course and possible outcomes in pediatric patients. Monkeypox seems scary, but it is still a sporadic disease, especially in pediatrics. However, it is always good to be aware of health risks.

**REFERENCES**

1 Guarner J, Del Rio C, Malani PN. Monkeypox in 2022-What Clinicians Need to Know. *JAMA* 2022; 328: 139-140 [PMID: 35696257 DOI: 10.1001/jama.2022.10802]

2 Apichaidejudom N. Monkeypox virus in 2022 outbreak: what do we need to know? *IJRP* 2022; **110:** 620-627 [DOI: 10.47119/IJRP10011011020223958]

3 Wei F, Peng Z, Jin Z, Wang J, Xu X, Zhang X, Xu J, Ren Z, Bai Y, Wang X, Lu B, Wang Z, Xu J, Huang S. Study and prediction of the 2022 global monkeypox epidemic. *J Biosaf Biosecur* 2022; 4: 158-162 [PMID: 36573222 DOI: 10.1016/j.jobb.2022.12.001]

4 Moore MJ, Rathish B, Zahra F. Mpox (Monkeypox) [Updated 2022 Nov 30]. In: StatPearls [DOI:10.1093/jamia/ocac127]

5 **Cho CT**, Wenner HA. Monkeypox virus. Bacteriol Rev 1973; **37:** 1-18 [PMID: 4349404 DOI: 10.1128/br.37.1.1-18.1973]

6 Long B, Koyfman A, Gottlieb M, Liang SY, Carius BM, Chavez S, Brady WJ. Monkeypox: A focused narrative review for emergency medicine clinicians. *Am J Emerg Med* 2022; 61: 34-43 [PMID: 36030595 DOI: 10.1016/j.ajem.2022.08.026]

7 **Ogoina D**, Izibewule JH, Ogunleye A, Ederiane E, Anebonam U, Neni A, Oyeyemi A, Etebu EN, Ihekweazu C. The 2017 human monkeypox outbreak in Nigeria-Report of outbreak experience and response in the Niger Delta University Teaching Hospital, Bayelsa State, Nigeria. *PLoS One* 2019; **14:** e0214229 [PMID: 30995249 DOI: 10.1371/journal.pone.0214229]

8 Vaughan A, Aarons E, Astbury J, Brooks T, Chand M, Flegg P, Hardman A, Harper N, Jarvis R, Mawdsley S, McGivern M, Morgan D, Morris G, Nixon G, O'Connor C, Palmer R, Phin N, Price DA, Russell K, Said B, Schmid ML, Vivancos R, Walsh A, Welfare W, Wilburn J, Dunning J. Human-to-Human Transmission of Monkeypox Virus, United Kingdom, October 2018. *Emerg Infect Dis* 2020; 26: 782-785 [PMID: 32023204 DOI: 10.3201/eid2604.191164]

9 Zachary KC, Shenoy ES. Monkeypox transmission following exposure in healthcare facilities in nonendemic settings: Low risk but limited literature. *Infect Control Hosp Epidemiol* 2022; 43: 920-924 [PMID: 35676244 DOI: 10.1017/ice.2022.152]

10 [DOI:10.54584/Lms.2022.18]

11 Huang YA, Howard-Jones AR, Durrani S, Wang Z, Williams PC. Monkeypox: A clinical update for paediatricians. *J Paediatr Child Health* 2022; 58: 1532-1538 [PMID: 35979896 DOI: 10.1111/jpc.16171]

12 Eurosurveillance Editorial team, Source of US monkeypox outbreak of identified, and CDC issues updated interim guidance for prevention and treatment of monkeypox. Eurosurveillance, [Volume 7, Issue 27, 03/Jul/2003](https://www.eurosurveillance.org/content/eurosurvweeklyarchive/7/27). Available from: https://www.eurosurveillance.org/content/10.2807/esw.07.27.02251-en

13 Saijo M, Ami Y, Suzaki Y, Nagata N, Iwata N, Hasegawa H, Iizuka I, Shiota T, Sakai K, Ogata M, Fukushi S, Mizutani T, Sata T, Kurata T, Kurane I, Morikawa S. Virulence and pathophysiology of the Congo Basin and West African strains of monkeypox virus in non-human primates. *J Gen Virol* 2009; 90: 2266-2271 [PMID: 19474247 DOI: 10.1099/vir.0.010207-0]

14 **Han JH**, Nachamkin I, Coffin SE, Gerber JS, Fuchs B, Garrigan C, Han X, Bilker WB, Wise J, Tolomeo P, Lautenbach E; Prevention Epicenters Program of the Centers for Disease Control and Prevention. Use of a Combination Biomarker Algorithm To Identify Medical Intensive Care Unit Patients with Suspected Sepsis at Very Low Likelihood of Bacterial Infection. *Antimicrob Agents Chemother* 2015; **59:** 6494-6500 [PMID: 26239984 DOI: 10.1128/AAC.00958-15]

15 **Cheng K**, Guo Q, Zhou Y, Wu H. Concern over monkeypox outbreak: What can we learn from the top 100 highly cited articles in monkeypox research? *Travel Med Infect Dis* 2022; **49:** 102371 [PMID: 35690319 DOI: 10.1016/j.tmaid.2022.102371]

16 **Singh H**, Mounika B, Priya KPL, Tiwari HD, Rajesh D. Choice of grafting options post apicectomy procedure by specialist endodontist: An original research. *Int J Health Sci* 2022; **6:** 10318–10324 [DOI: 10.53730/ijhs.v6nS6.12724]

17 Kaler J, Hussain A, Flores G, Kheiri S, Desrosiers D. Monkeypox: A Comprehensive Review of Transmission, Pathogenesis, and Manifestation. *Cureus* 2022; **14:** e26531 [PMID: 35928395 DOI: 10.7759/cureus.26531]

18 **Andrea M.** McCollum, Inger K. Damon, Human Monkeypox [*Clinical Infectious Diseases*, Volume 58, Issue 2, 15 January 2014, Pages 260–267]

19 Adler H, Gould S, Hine P, Snell LB, Wong W, Houlihan CF, Osborne JC, Rampling T, Beadsworth MB, Duncan CJ, Dunning J, Fletcher TE, Hunter ER, Jacobs M, Khoo SH, Newsholme W, Porter D, Porter RJ, Ratcliffe L, Schmid ML, Semple MG, Tunbridge AJ, Wingfield T, Price NM; NHS England High Consequence Infectious Diseases (Airborne) Network. Clinical features and management of human monkeypox: a retrospective observational study in the UK. *Lancet Infect Dis* 2022; 22: 1153-1162 [PMID: 35623380 DOI: 10.1016/S1473-3099(22)00228-6]

20 Mbala PK, Huggins JW, Riu-Rovira T, Ahuka SM, Mulembakani P, Rimoin AW, Martin JW, Muyembe JT. Maternal and Fetal Outcomes Among Pregnant Women With Human Monkeypox Infection in the Democratic Republic of Congo. *J Infect Dis* 2017; 216: 824-828 [PMID: 29029147 DOI: 10.1093/infdis/jix260]

21 Chaudhari S, Treffeisen L, Virk J, Parikh T, Gopalakrishnan Ravikumar NP, Goti AM, Goyal L, Yashi K. The 2022 Monkeypox Epidemic and What Has Led to the Current State of the Disease in the US: A Systematic Review. *Cureus* 2023; **15:** e33515 [PMID: 36779102 DOI: 10.7759/cureus.33515]

22 Rizk JG, Lippi G, Henry BM, Forthal DN, Rizk Y. Prevention and Treatment of Monkeypox. *Drugs* 2022; 82: 957-963 [PMID: 35763248 DOI: 10.1007/s40265-022-01742-y]

23 Zimmermann P, Curtis N. Monkeypox-What Pediatricians Need to Know. *Pediatr Infect Dis J* 2022; 41: 1020-1031 [PMID: 36322796 DOI: 10.1097/INF.0000000000003720]

24 Gaeta F, De Caro F, Franci G, Pagliano P, Vajro P, Mandato C. Monkeypox Infection 2022: An Updated Narrative Review Focusing on the Neonatal and Pediatric Population. *Children (Basel)* 2022; 9 [PMID: 36553276 DOI: 10.3390/children9121832]

25 **Singhal T**, Kabra SK, Lodha R. Monkeypox: A Review. *Indian J Pediatr* 2022; **89:** 955-960 [PMID: 35947269 DOI: 10.1007/s12098-022-04348-0]

26 [Centers for Disease Control and Prevention](http://www.cdc.gov/), [National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)](http://www.cdc.gov/ncezid/index.html), [Division of High-Consequence Pathogens and Pathology (DHCPP)](http://www.cdc.gov/ncezid/dhcpp/index.html), Clinical Considerations for Mpox in Children and Adolescents, September 1, 2023

**Footnotes**

**Conflict-of-interest statement:** All the authors declare that they have no conflicts of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** June 2, 2023

**First decision:** August 2, 2023

**Article in press:**

**Specialty type:** Pediatrics

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Bekele BK, Ethiopia; Li S, China **S-Editor:** Liu JH **L-Editor:** Webster JR **P-Editor:**

**Table 1 Case definition and clinical features**

|  |  |
| --- | --- |
| **Suspect case** | New-onset typical rash |
| Fulfill one of the epidemiologic criteria and have a solid clinical possibility of monkeypox |
| **Probable case** | No other possible orthopoxviral exposure (*e.g.*, vaccination), and evidence of the presence of  |
| orthopoxviral DNA by PCR in the patient’s sample |
| Presence of orthopoxvirus using immunohistochemical or electron microscopy testing methods |
| Positive anti-orthopoxviral IgM antibody after onset of rash for a duration of 4 to 56 d. Men who practice sex with men |
| **Confirmed case** | Evidence of monkeypox virus DNA detected by PCR in a patient specimen or detection of virus in clinical specimen culture |
| Epidemiological criteria: Within three weeks of beginning the illness: Possible exposure to a person with a characteristic rash or who was diagnosed with monkeypox or a probable case, or following intimate exposure to individuals with monkeypox-like symptoms. Travel to a monkeypox endemic country outside the United States or a country with a monkeypox outbreak, or contact with a dead or live wild animal or pet from an endemic African region or a product obtained from such animals |

DNA: Deoxyribonucleic acid; PCR: Polymerase chain reaction; IgM: Immunoglobulin M.

**Table 2 Monkeypox symptoms and treatment options**

|  |  |
| --- | --- |
| **Monkeypox symptoms** | **Treatment options**  |
| Monkeypox symptoms: Itchy, painful pimple/blister-like rash with several stages  | Oral antihistamines, creams, and lotions such as calamine lotion. Keep the rash covered, do not scratch, soak in a warm bath, use oatmeal |
| Fever, chills, lymph node swelling, body ache, URI symptoms | Symptomatic pain medications |
| Severe disease involving eyes, mouth, throat, genitals and anus | Antiviral tecovirimat |

URI: Upper respiratory infection.